Anti-Tumor effect of a novel soluble recombinant human endostatin: Administered as a single agent or in combination with chemotherapy agents in mouse tumor models

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Ren, Zhihua ^a,c   Wang, Yanan ^b   Jiang, Wenhong ^a   Dai, Wei ^c,d   Jiang, Yongping ^a,c  

^a Biopharmagen Corp   (China)

^b SUZHOU MUNICIPAL HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; GLYCINE; HISTIDINE; RECOMBINANT ENDOSTATIN; SERINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENDOSTATIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; DRUG POTENTIATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MELANOMA B16; METASTASIS; MOUSE; NONHUMAN; PERITUMORAL DRUG ADMINISTRATION; PROTEIN FOLDING; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; ISOLATION AND PURIFICATION; PROTEIN REFOLDING; SOLUBILITY; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DISEASE MODELS, ANIMAL; ENDOSTATINS; ESCHERICHIA COLI; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROTEIN REFOLDING; RECOMBINANT PROTEINS; SOLUBILITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907195018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107823     Document Type: Article

References (57)

1. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
2. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424.
3. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, et al. (2005) Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4: 1399-1408.
4. OReilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
5. Boehm T, Folkman J, Browder T, OReilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407.
6. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, et al. (2001) Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7: 3366-3374.
7. Eder JP, Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, et al. (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772-3784.
8. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, et al. (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24: 3555-3561.
9. Sun L, Ye HY, Zhang YH, Guan YS, Wu H (2007) Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol 13: 6115-6118.
10. Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, et al. (2003) Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res 9: 4619-4626.
11. Roy Choudhury S, Karmakar S, Banik NL, Ray SK (2012) Targeting angiogenesis for controlling neuroblastoma. J Oncol: 782020.
12. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, et al. (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804-3814.
13. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, et al. (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197.
14. Boehm T, Pirie-Shepherd S, Trinh LB, Shiloach J, Folkman J (1999) Disruption of the KEX1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Yeast 15: 563-572.
15. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J (2007) Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170: 1-15.
16. Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, et al. (2003) Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 9: 1211-1217.
17. Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670-3684.
18. Kaya M, Wada T, Nagoya S, Yamashita T (2007) Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci 12: 562-567.
19. Kerbel RS, Viloria-Petit A, Klement G, Rak J (2000) Accidental antiangiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36: 1248-1257.
20. Klement G, Baruchel S, Rak J, Man S, Clark K, et al. (2000) Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-24.
21. Cabebe E, Wakelee H (2007) Role of anti-Angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8: 15-27.
22. Jiang Y, Jiang W, Qiu Y, Dai W Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys. J Hematol Oncol 4: 28.
23. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, et al. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423.
24. Hoshi H, McKeehan WL (1984) Brain-And liver cell-derived factors are required for growth of human endothelial cells in serum-free culture. Proc Natl Acad Sci U S A 81: 6413-6417.
25. Briles EB, Kornfeld S (1978) Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 60: 1217-1222.
26. Luo D, Cheng SC, Xie H, Xie Y (1999) Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20: 331-340.
27. Xiong X, Sui M, Fan W, Kraft AS (2007) Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther 6: 1067-1073.
28. Song S JW, Jiang Y (2012) Large-scale production, refolding, and purification of a novel recombinant human granulocyte colony stimulating factor. Chinese Journal of Biomedical Engineering 31: 552-557.
29. Folkman J (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539.
30. Saphir A (1997) Angiogenesis: the unifying concept in cancer? J Natl Cancer Inst 89: 1658-1659.
31. Hagedorn M, Bikfalvi A (2000) Target molecules for anti-Angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 34: 89-110.
32. Harris AL (1998) Anti-Angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res 152: 341-352.
33. Brem H, Folkman J (1975) Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141: 427-439.
34. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
35. OReilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, et al. (1994) Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59: 471-482.
36. OReilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692.
37. Boehm T, OReilly M S, Keough K, Shiloach J, Shapiro R, et al. (1998) Zincbinding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252: 190-194.
38. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP (1999) Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 258: 345-352.
39. Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763.
40. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, et al. (2003) Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9: 377-382.
41. Kisker O, Becker CM, Prox D, Fannon M, DAmato R, et al. (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674.
42. Scheer A, Costa T, Fanelli F, De Benedetti PG, Mhaouty-Kodja S, et al. (2000) Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-Adrenergic receptor: effects on receptor isomerization and activation. Mol Pharmacol 57: 219-231.
43. Hawtin SR, Simms J, Conner M, Lawson Z, Parslow RA, et al. (2006) Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation, and cell-surface expression. J Biol Chem 281: 38478-38488.
44. Joseph MK, Solomon LR, Petros AM, Cai J, Simmer RL, et al. (2004) Divergence of Genbank and human tumor Bcl-2 sequences and implications for binding affinity to key apoptotic proteins. Oncogene 23: 835-838.
45. Wu Y, Yang L, Hu B, Liu JY, Su JM, et al. (2005) Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs 16: 551-557.
46. Jia Y, Liu M, Huang W, Wang Z, He Y, et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res 18: 315-323.
47. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, et al. (2001) Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 61: 478-481.
48. Dong XP, Xiao TH, Dong H, Jiang N, Zhao XG Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. Asian Pac J Cancer Prev 14: 3079-3083.
49. Fu XH, Li J, Zou Y, Hong YR, Fu ZX, et al. Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Lett 312: 109-116.
50. Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone 57: 111-115.
51. Cui C, Mao L, Chi Z, Si L, Sheng X, et al. A phase II, randomized, doubleblind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 21: 1456-1463.
52. Zhang LP, Liao XY, Xu YM, Yan LJ, Yan GF, et al. Efficacy and safety of endostar(R) combined with chemotherapy in patients with advanced soft tissue sarcomas. Asian Pac J Cancer Prev 14: 4255-4259.
53. Calvo A, Feldman AL, Libutti SK, Green JE (2002) Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-Antigen transgenic mice. Cancer Res 62: 3934-3938.
54. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
55. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, et al. (2006) Anti-Angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun 349: 1073-1078.
56. Abdollahi A, Hlatky L, Huber PE (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74.
57. Prokopiou EM, Ryder SA, Walsh JJ Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 16: 503-524.